Literature DB >> 8093489

Induction of renal adenocarcinoma by a nonmutated erbB oncogene.

C A Taglienti-Sian1, B Banner, R J Davis, H L Robinson.   

Abstract

Oncogenicity tests have revealed that a nonmutated erbB oncogene induces renal adenocarcinoma in addition to erythroblastosis. The erbB oncogene is a truncated form of the chicken epidermal growth factor receptor that lacks the extracellular ligand-binding domain. Previously, the nonmutated erbB oncogene has been reported to cause only erythroblastosis. The expansion of the disease potential of erbB to additional neoplasms has been associated with mutations (truncations, deletions, and point mutations) within the erbB gene. Our results indicate that a nonmutated virally expressed erbB oncogene (REB-c) causes a 100% incidence of renal neoplasia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093489      PMCID: PMC237473     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma.

Authors:  E R Sargent; L G Gomella; A Belldegrun; W M Linehan; A Kasid
Journal:  J Urol       Date:  1989-11       Impact factor: 7.450

2.  Dissecting the activating mutations in v-erbB of avian erythroblastosis virus strain R.

Authors:  H K Shu; R J Pelley; H J Kung
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

3.  Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers.

Authors:  M R Freeman; R Washecka; L W Chung
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

4.  Segmental distribution of epidermal growth factor binding sites in rabbit nephron.

Authors:  M D Breyer; R Redha; J A Breyer
Journal:  Am J Physiol       Date:  1990-10

Review 5.  Potential physiologic roles for epidermal growth factor in the kidney.

Authors:  R C Harris
Journal:  Am J Kidney Dis       Date:  1991-06       Impact factor: 8.860

6.  Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas.

Authors:  P E Petrides; S Bock; J Bovens; R Hofmann; G Jakse
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

7.  Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue.

Authors:  J H Mydlo; J Michaeli; C Cordon-Cardo; A S Goldenberg; W D Heston; W R Fair
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

8.  Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.

Authors:  H K Shu; R J Pelley; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

9.  Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma.

Authors:  U Weidner; S Peter; T Strohmeyer; R Hussnätter; R Ackermann; H Sies
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

Review 10.  Epidermal growth factor and the kidney.

Authors:  D A Fisher; E C Salido; L Barajas
Journal:  Annu Rev Physiol       Date:  1989       Impact factor: 19.318

View more
  3 in total

1.  Tissue- and transformation-specific phosphotyrosyl proteins in v-erbB-transformed cells.

Authors:  M J McManus; D C Connolly; N J Maihle
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

2.  Tyrosine kinase activity may be necessary but is not sufficient for c-erbB1-mediated tissue-specific tumorigenicity.

Authors:  D C Connolly; S L Toutenhoofd; N J Maihle
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

3.  Disease specificity of kinase domains: the src-encoded catalytic domain converts erbB into a sarcoma oncogene.

Authors:  C M Chang; H K Shu; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.